Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OMCL's Cash to Debt is ranked higher than
82% of the 2122 Companies
in the Global Health Information Services industry.

( Industry Median: 4.47 vs. OMCL: No Debt )
OMCL' s 10-Year Cash to Debt Range
Min: 0.42   Max: No Debt
Current: No Debt

Equity to Asset 0.69
OMCL's Equity to Asset is ranked higher than
78% of the 2058 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. OMCL: 0.69 )
OMCL' s 10-Year Equity to Asset Range
Min: -0.57   Max: 0.78
Current: 0.69

-0.57
0.78
Interest Coverage No Debt
OMCL's Interest Coverage is ranked higher than
72% of the 1336 Companies
in the Global Health Information Services industry.

( Industry Median: 1106.00 vs. OMCL: No Debt )
OMCL' s 10-Year Interest Coverage Range
Min: 44.6   Max: 2381.5
Current: No Debt

44.6
2381.5
F-Score: 5
Z-Score: 5.56
M-Score: -2.26
WACC vs ROIC
9.14%
12.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.25
OMCL's Operating margin (%) is ranked higher than
84% of the 2107 Companies
in the Global Health Information Services industry.

( Industry Median: 5.51 vs. OMCL: 11.25 )
OMCL' s 10-Year Operating margin (%) Range
Min: -29   Max: 9.27
Current: 11.25

-29
9.27
Net-margin (%) 6.92
OMCL's Net-margin (%) is ranked higher than
80% of the 2107 Companies
in the Global Health Information Services industry.

( Industry Median: 3.65 vs. OMCL: 6.92 )
OMCL' s 10-Year Net-margin (%) Range
Min: -30.86   Max: 20.32
Current: 6.92

-30.86
20.32
ROE (%) 8.20
OMCL's ROE (%) is ranked higher than
74% of the 2039 Companies
in the Global Health Information Services industry.

( Industry Median: 6.71 vs. OMCL: 8.20 )
OMCL' s 10-Year ROE (%) Range
Min: -28.06   Max: 28.62
Current: 8.2

-28.06
28.62
ROA (%) 5.76
OMCL's ROA (%) is ranked higher than
78% of the 2130 Companies
in the Global Health Information Services industry.

( Industry Median: 3.51 vs. OMCL: 5.76 )
OMCL' s 10-Year ROA (%) Range
Min: -7.04   Max: 17.93
Current: 5.76

-7.04
17.93
ROC (Joel Greenblatt) (%) 59.94
OMCL's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 2106 Companies
in the Global Health Information Services industry.

( Industry Median: 33.24 vs. OMCL: 59.94 )
OMCL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -113.41   Max: 141.68
Current: 59.94

-113.41
141.68
Revenue Growth (3Y)(%) 17.00
OMCL's Revenue Growth (3Y)(%) is ranked higher than
89% of the 1683 Companies
in the Global Health Information Services industry.

( Industry Median: 5.40 vs. OMCL: 17.00 )
OMCL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -53.3   Max: 17.5
Current: 17

-53.3
17.5
EBITDA Growth (3Y)(%) 39.70
OMCL's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 1393 Companies
in the Global Health Information Services industry.

( Industry Median: 6.20 vs. OMCL: 39.70 )
OMCL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -14.1   Max: 124.1
Current: 39.7

-14.1
124.1
EPS Growth (3Y)(%) 64.70
OMCL's EPS Growth (3Y)(%) is ranked higher than
95% of the 1276 Companies
in the Global Health Information Services industry.

( Industry Median: 6.50 vs. OMCL: 64.70 )
OMCL' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.7   Max: 260.9
Current: 64.7

-69.7
260.9
» OMCL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OMCL Guru Trades in Q1 2014

Paul Tudor Jones 14,400 sh (-26.43%)
Joel Greenblatt 45,947 sh (-36.38%)
» More
Q2 2014

OMCL Guru Trades in Q2 2014

Ken Fisher 410,000 sh (New)
Jim Simons 103,943 sh (New)
Paul Tudor Jones 16,552 sh (+14.94%)
Joel Greenblatt 43,389 sh (-5.57%)
» More
Q3 2014

OMCL Guru Trades in Q3 2014

Paul Tudor Jones 24,905 sh (+50.47%)
Ken Fisher 492,478 sh (+20.12%)
Jim Simons 90,443 sh (-12.99%)
Joel Greenblatt 35,084 sh (-19.14%)
» More
Q4 2014

OMCL Guru Trades in Q4 2014

Ken Fisher 559,000 sh (+13.51%)
Joel Greenblatt Sold Out
Jim Simons 90,343 sh (-0.11%)
Paul Tudor Jones 9,979 sh (-59.93%)
» More
» Details

Insider Trades

Latest Guru Trades with OMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.90
OMCL's P/E(ttm) is ranked higher than
73% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 60.50 vs. OMCL: 43.90 )
OMCL' s 10-Year P/E(ttm) Range
Min: 8.94   Max: 795.88
Current: 43.9

8.94
795.88
Forward P/E 24.51
OMCL's Forward P/E is ranked higher than
81% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. OMCL: 24.51 )
N/A
PE(NRI) 42.60
OMCL's PE(NRI) is ranked higher than
75% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 63.20 vs. OMCL: 42.60 )
OMCL' s 10-Year PE(NRI) Range
Min: 8.97   Max: 676.5
Current: 42.6

8.97
676.5
P/B 3.00
OMCL's P/B is ranked higher than
68% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 3.39 vs. OMCL: 3.00 )
OMCL' s 10-Year P/B Range
Min: 0.96   Max: 8.11
Current: 3

0.96
8.11
P/S 2.80
OMCL's P/S is ranked higher than
58% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 2.68 vs. OMCL: 2.80 )
OMCL' s 10-Year P/S Range
Min: 0.94   Max: 4.69
Current: 2.8

0.94
4.69
PFCF 51.60
OMCL's PFCF is ranked higher than
72% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 99.61 vs. OMCL: 51.60 )
OMCL' s 10-Year PFCF Range
Min: 8   Max: 730
Current: 51.6

8
730
POCF 24.68
OMCL's POCF is ranked higher than
73% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 29.38 vs. OMCL: 24.68 )
OMCL' s 10-Year POCF Range
Min: 6.97   Max: 1010
Current: 24.68

6.97
1010
EV-to-EBIT 22.57
OMCL's EV-to-EBIT is ranked higher than
77% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 35.54 vs. OMCL: 22.57 )
OMCL' s 10-Year EV-to-EBIT Range
Min: -1140.1   Max: 424.9
Current: 22.57

-1140.1
424.9
PEG 2.04
OMCL's PEG is ranked higher than
92% of the 2301 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. OMCL: 2.04 )
OMCL' s 10-Year PEG Range
Min: 0.5   Max: 42.93
Current: 2.04

0.5
42.93
Shiller P/E 84.70
OMCL's Shiller P/E is ranked higher than
76% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. OMCL: 84.70 )
OMCL' s 10-Year Shiller P/E Range
Min: 15.61   Max: 299.13
Current: 84.7

15.61
299.13
Current Ratio 2.41
OMCL's Current Ratio is ranked higher than
76% of the 2088 Companies
in the Global Health Information Services industry.

( Industry Median: 1.87 vs. OMCL: 2.41 )
OMCL' s 10-Year Current Ratio Range
Min: 0.64   Max: 5.21
Current: 2.41

0.64
5.21
Quick Ratio 2.12
OMCL's Quick Ratio is ranked higher than
74% of the 2088 Companies
in the Global Health Information Services industry.

( Industry Median: 1.77 vs. OMCL: 2.12 )
OMCL' s 10-Year Quick Ratio Range
Min: 0.4   Max: 4.95
Current: 2.12

0.4
4.95
Days Inventory 55.49
OMCL's Days Inventory is ranked higher than
73% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 153.43 vs. OMCL: 55.49 )
OMCL' s 10-Year Days Inventory Range
Min: 35.43   Max: 128.75
Current: 55.49

35.43
128.75
Days Sales Outstanding 68.52
OMCL's Days Sales Outstanding is ranked higher than
77% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 82.25 vs. OMCL: 68.52 )
OMCL' s 10-Year Days Sales Outstanding Range
Min: 44.3   Max: 88.48
Current: 68.52

44.3
88.48

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.77
OMCL's Price/Net Current Asset Value is ranked higher than
81% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. OMCL: 11.77 )
OMCL' s 10-Year Price/Net Current Asset Value Range
Min: 1.59   Max: 33.5
Current: 11.77

1.59
33.5
Price/Tangible Book 6.33
OMCL's Price/Tangible Book is ranked higher than
68% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 8.75 vs. OMCL: 6.33 )
OMCL' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 16.59
Current: 6.33

1.2
16.59
Price/DCF (Projected) 2.14
OMCL's Price/DCF (Projected) is ranked higher than
79% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 8.50 vs. OMCL: 2.14 )
OMCL' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 50.25
Current: 2.14

0.94
50.25
Price/Median PS Value 1.29
OMCL's Price/Median PS Value is ranked higher than
69% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 1.30 vs. OMCL: 1.29 )
OMCL' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 2.22
Current: 1.29

0.22
2.22
Price/Peter Lynch Fair Value 1.71
OMCL's Price/Peter Lynch Fair Value is ranked higher than
92% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. OMCL: 1.71 )
OMCL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.69   Max: 23.38
Current: 1.71

0.69
23.38
Price/Graham Number 3.57
OMCL's Price/Graham Number is ranked higher than
77% of the 2302 Companies
in the Global Health Information Services industry.

( Industry Median: 57.00 vs. OMCL: 3.57 )
OMCL' s 10-Year Price/Graham Number Range
Min: 1.29   Max: 18.72
Current: 3.57

1.29
18.72
Earnings Yield (Greenblatt) 4.40
OMCL's Earnings Yield (Greenblatt) is ranked higher than
73% of the 2105 Companies
in the Global Health Information Services industry.

( Industry Median: 3.40 vs. OMCL: 4.40 )
OMCL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15.9
Current: 4.4

0.2
15.9
Forward Rate of Return (Yacktman) 44.43
OMCL's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 1116 Companies
in the Global Health Information Services industry.

( Industry Median: 12.97 vs. OMCL: 44.43 )
OMCL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.1   Max: 45
Current: 44.43

-5.1
45

Business Description

Industry: Application Software » Health Information Services
Compare:CERN, CTRX, ATHN, MDRX, AH » details
Traded in other countries:OC9.Germany,
Omnicell, Inc., is a Delaware corporation incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company is a provider of automation and business information solutions enabling healthcare systems to streamline the medication administration process and manage costly medical supplies for increased operational efficiency and enhanced patient safety. The Company's automation, analytics and medication adherence solutions in hospitals and longer-term care environments are designed to enable healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies and are intended to enhance patient safety, reduce medication errors, reduce operating costs, improve workflow, and increase operational efficiency. Approximately 6,000 hospitals, institutional pharmacies, and retail pharmacies use Company's products worldwide. The Company is organized into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers, and Non-Acute Care, which primarily includes products and services sold to customers outside of the hospital setting. In acute care facilities, its solutions use advanced, software‑based medication control and tracking algorithms that interact with hardware security features, resulting in a system that provides both the pharmacist and the nurse real-time safety controls. It also provides medication bar code verification at every step of the medication administration process, from entry to the hospital through the administration of the medication to a patient. Its systems enables customers to reduce or eliminate inefficiencies such as manual tracking and reconciliations, nursing time spent in obtaining medications and in performing inventory control and extraneous process steps. Similar to its medication solutions, Company's medical and surgical supply systems provide hospitals control over consumable supplies critical to providing quality healthcare. Its solutions provide inventory control software that is designed to ensure critical supplies are always stocked in the right locations. It also offers analytics and reporting software for pharmacists and material managers to more easily manage inventory flow, tracking and optimization. The Non-Acute Care segment represents products sold outside the hospital setting and includes medication adherence products sold under the brand name of MTS, and dispensing systems sold under the Omnicell brand. The MTS products consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities. These systems use consumable medication punch cards and specialized machines that allow the pharmacies to automatically or semi-automatically assemble, fill and seal drugs into
» More Articles for OMCL

Headlines

Articles On GuruFocus.com
Ken Fisher's Top 5 New Portfolio Stocks Jul 28 2014 
comment on OMCL May 26 2013 
Omnicell Inc. (OMCL) V.P., Finance & CFO Robin Gene Seim sells 1,250 Shares Feb 04 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 11,997 Shares Jan 25 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 11,997 Shares Jan 13 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 937 Shares Jan 06 2011 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 3,351 Shares Dec 23 2010 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 1,500 Shares Dec 04 2010 
Omnicell Inc. (OMCL) V.P., Finance & CFO Robin Gene Seim sells 4,265 Shares Dec 01 2010 
Omnicell Inc. (OMCL) President and CEO Randall A Lipps sells 11,372 Shares Oct 23 2010 

More From Other Websites
OMNICELL, INC Files SEC form 10-K, Annual Report Mar 30 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Mar 30 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OMNICELL, INC. of PENDENCY OF CLASS... Mar 27 2015
Omnicell to Present Expanded Medication Management Integration at the European Association of... Mar 25 2015
Omnicell, Inc. Receives Expected Nasdaq Notification of Noncompliance Mar 24 2015
Robbins Arroyo LLP: Omnicell, Inc. (OMCL) Misled Shareholders According to a Recently Filed Class... Mar 23 2015
Omnicell, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate... Mar 23 2015
INVESTOR ALERT: Class Action Lawsuit Against Omnicell, Inc. Announced by Glancy Binkow & Goldberg... Mar 23 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Mar 23 2015
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Mar 20 2015
OMNICELL, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Mar 20 2015
INVESTOR ALERT: Investigation on Behalf of Investors of Omnicell, Inc. Announced by Law Offices of... Mar 20 2015
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Omnicell, Inc. Mar 20 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OMNICELL, INC. of PENDENCY OF... Mar 20 2015
Harwood Feffer LLP Announces Investigation of Omnicell, Inc. Mar 19 2015
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against... Mar 19 2015
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action against Omnicell,... Mar 19 2015
Pomerantz Law Firm Announces the Filing of a Class Action Against Omnicell, Inc. and Certain... Mar 19 2015
Omnicell Tweaks '15 View on Legal Issues, Impending Buyout - Analyst Blog Mar 18 2015
OMNICELL, INC Files SEC form 8-K, Regulation FD Disclosure Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK